PARP-inhibitors in a non‐oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open
In the last three months, the whole scientific community has shifted its focus to the fight against the COVI-2 infection (COVID-19) trying to use different medications to save the patients' life. In some studies, the results were completely inconclusive, as in the case of chloroquine. However,...
Main Author: | Ettore Capoluongo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220307290 |
Similar Items
-
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
by: Luyao Wang, et al.
Published: (2017-10-01) -
BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
by: Mary-Ann Xavier, et al.
Published: (2021-08-01) -
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
by: Ahrum Min, et al.
Published: (2020-02-01) -
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
by: Michela Palleschi, et al.
Published: (2021-07-01) -
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
by: Abdullah Alhusaini, et al.
Published: (2021-08-01)